natgillin/translations-raw huggingface dataset:
• In patients with previous malignant disease, the doctor should give special attention to signs and symptoms of relapse. • In patients with a history of brain lesions, the patient should be examined frequently for a progression or recurrence of the lesion. • Children with Prader-Willi syndrome should not be treated with NutropinAq unless they are also suffering from growth hormone failure. • In patients with acute critical illness in intensive care units, the doctor should carefully evaluate the safety of continuing somatropin treatment. • If during growing a limp or hip or knee pain develops, please ask the doctor for advice. • Scoliosis may progress in any child during rapid growth.
• Pri bolnikih s predhodno maligno boleznijo mora zdravnik posebno pozornost nameniti znakom in simptomom ponovitve. • V primeru anamneze o možganski leziji je treba bolnika pogosto pregledati glede napredovanja ali ponovitve lezije. • Otroci s Prader- Willijevim sindromom naj ne bi bili zdravljeni z NutropinAq, razen če imajo pomanjkanje rastnega hormona. • Pri bolnikih z akutno kritično boleznijo v enoti za intenzivno nego mora zdravnik skrbno pretehtati varnost nadaljnjega zdravljenja s somatropinom. • Če se med rastjo pojavijo šepanje ali bolečine v kolku ali kolenu, se posvetujte z zdravnikom. • Skolioza lahko napreduje pri vsakem otroku s hitro rastjo.
Signs of scoliosis should be monitored during treatment. • In patients receiving NutropinAq, evidence of glucose intolerance should be monitored.
Znake skolioze je treba spremljati med zdravljenjem. • Bolnike, ki dobivajo NutropinAq, je treba nadzorovati glede znakov motene tolerance za glukozo.
If the patient also has diabetes mellitus, please consult the doctor regularly during NutropinAq therapy.
Če imate tudi diabetes mellitus, se med zdravljenjem z NutropinAq redno posvetujte z zdravnikom.
The insulin dose may require adjustment after somatropin therapy is started. • This medicinal product contains 82 mg of sodium per cartridge.
Po začetku zdravljenja s somatropinom utegne biti potrebna prilagoditev odmerka insulina. • To zdravilo vsebuje 82 mg natrija na vložek.
To be taken in consideration by patients on a controlled sodium diet. • If symptoms like visual changes, headache, nausea and/ or vomiting occur, especially within the first eight weeks after starting somatropin therapy, please ask the doctor for advice. • In case of an untreated decrease of thyroid gland function (hypothyroidism), the optimal response to somatropin may be reduced.
To naj vzamejo na znanje bolniki, ki so na dieti z znižanjem natrija. • Če se, zlasti v prvih osmih tednih po začetku zdravljenja s somatropinom, pojavijo simptomi, kot so npr. motnje vida, glavobol, siljenje na bruhanje in/ ali bruhanje, se posvetujte z zdravnikom. • V primeru nezdravljenega zmanjšanja delovanja žleze ščitnice (hipotiroidizma) se lahko optimalni odziv na somatropin zmanjša.
Severe hypothyroidism has to be treated prior to start of NutropinAq therapy. • Since somatropin therapy following renal transplantation has not been adequately tested, growth hormone treatment should be terminated after that surgery. • Adrenocorticotrophic Hormone (ACTH) -deficient patients should consult the doctor regularly during growth hormone therapy.
Hud hipotiroidizem je treba zdraviti pred začetkom terapije z NutropinAq. • Zdravljenje s somatropinom po presaditvi ledvice ni zadostno preizkušeno, zato je treba zdravljenje z rastnim hormonom po takšni operaciji končati. • Bolniki s pomanjkanjem ACTH se morajo med zdravljenjem z rastnim hormonom redno posvetovati z zdravnikom.
The glucocorticoid replacement therapy may require adjustment after NutropinAq therapy has been started.
Po začetku zdravljenja z NutropinAq utegne biti potrebna prilagoditev nadomestnega zdravljenja z glukokortikoidi.
• Concomitant treatment with glucocorticoids may reduce the growth-promoting effect of somatropin. • Because somatropin may reduce insulin sensitivity, patients with diabetes mellitus may require adjustment of their antidiabetic therapy. • During concomitant administration of somatropin with corticosteroids, sex steroids, anticonvulsants or cyclosporin, please ask the doctor for advice.
• Sočasno zdravljenje z glukokortikoidi lahko zmanjša spodbujevalni učinek somatropina na rast. • Somatropin lahko zmanjša občutljivost za insulin, zato utegne biti pri bolnikih z diabetesom mellitusom potrebna prilagoditev antidiabetične terapije. • Glede sočasne uporabe somatropina s kortikosteroidi, spolnimi steroidi, antiepileptičnimi zdravili ali ciklosporinom se posvetujte z zdravnikom.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription
Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
NutropinAq therapy should be discontinued if pregnancy occurs.
Zdravljenje z NutropinAq je treba prekiniti, če ženska zanosi.
However, absorption of intact protein from the gastrointestinal tract of the infant is unlikely.
Ni znano, ali se somatropin izloča v materino mleko, vendar pa absorpcija nespremenjene beljakovine iz dojenčkovih prebavil ni verjetna.
Please ask your doctor or pharmacist for advice before taking any medicine.
Posvetujte se z zdravnikom ali farmacevtom, preden vzamete katerokoli zdravilo.
25 3.
25 3.
HOW TO USE NutropinAq
KAKO UPORABLJATI ZDRAVILO NutropinAq
The diagnosis and management of somatropin therapy should be initiated and monitored by adequately experienced physicians.
Diagnozo morajo postaviti, vodenje zdravljenja s somatropinom pa začeti in nadzorovati ustrezno izkušeni zdravniki.
The doctor will advise you about the individualised dose of NutropinAq.
Zdravnik vas bo seznanil z individualiziranim odmerkom NutropinAq.
Please do not change the dosage without consulting the doctor or pharmacist.
Ne spreminjajte odmerka, ne da bi se posvetovali z zdravnikom ali farmacevtom.
In general, the dosage will be calculated according to the following rules:
Praviloma se odmerek izračuna po naslednjih pravilih:
Growth failure associated with chronic renal insufficiency:
Zaostanek v rasti, povezan s kronično insuficienco ledvic:
Somatropin therapy may be continued up to the time of renal transplantation.
Zdravljenje s somatropinom se lahko nadaljuje do presaditve ledvice.
Growth hormone deficiency in adults:
Pomanjkanje rastnega hormona pri odraslih:
Low initial doses of 0.15 - 0.3 mg given as a daily subcutaneous injection.
Majhni začetni odmerki od 0, 15 do 0, 3 mg v vsakodnevni subkutani injekciji.
The dose may be increased stepwise by the doctor according to the patient ’ s individual requirements.
Zdravnik lahko odmerek postopoma povečuje glede na individualne bolnikove potrebe.
The final dose seldom exceeds 1.0 mg/ day.
Končni odmerek redko presega 1, 0 mg/ dan.
In general, the lowest efficacious dose should be received.
Praviloma mora bolnik dobivati najmanjši učinkoviti odmerek.
For older or overweight patients lower doses may be necessary.
Pri starejših bolnikih in bolnikih s prekomerno telesno maso utegnejo biti potrebni manjši odmerki.
NutropinAq is designed for use only with the NutropinAq Pen.
NutropinAq je namenjen samo za uporabo z injekcijskim peresnikom NutropinAq Pen.
Please administer the prescribed dose of NutropinAq solution for injection subcutaneously each day and change the site of injection each time.
Predpisani odmerek raztopine za injiciranje NutropinAq vbrizgajte subkutano vsak dan in vsakokrat zamenjajte mesto injiciranja.
At the start of therapy it is recommended that a doctor or a nurse give the injection and train you with the appropriate NutropinAq Pen to use with your NutropinAq cartridge.
Na začetku zdravljenja je priporočljivo, da injekcijo da zdravnik ali medicinska sestra in da vas usposobi uporabljati injekcijski peresnik NutropinAq Pen z vašim NutropinAq vložkom.
After training, the injection can be given by the patient or his/ her carer.
Po ustreznem usposabljanju si lahko injekcije daje bolnik sam ali mu jih daje oseba, ki skrbi zanj.
The medicine is supplied in a cartridge as a sterile solution with preservative for multiple use.
Zdravilo je na voljo v vložku kot sterilna raztopina s konzervansom za večkratno uporabo.
For each single injection please use a new, sterile injection needle.
Za vsako posamezno injiciranje uporabite novo, sterilno injekcijsko iglo.
Do not use the solution unless it is clear and not cloudy.
Raztopine ne uporabite, če ni bistra in je motna.
Please see also the instructions for use (on reverse).
Glejte tudi navodilo za uporabo (na hrbtni strani).
Treatment with somatropin is a long-term therapy.
Zdravljenje s somatropinom je dolgoročna terapija.
For further information please ask the doctor.
Za dodatne informacije se obrnite na zdravnika.
If more NutropinAq than recommended was injected, please consult the doctor.
Če ste uporabili več zdravila NutropinAq, kot je priporočeno, se posvetujte z zdravnikom.
Acute overdose could lead initially to a glucose decrease (hypoglycaemia) and subsequently to a glucose increase (hyperglycaemia).
Akutno preveliko odmerjanje lahko sprva povzroči znižanje glukoze (hipoglikemijo) in nato njeno zvišanje (hiperglikemijo).
Long-term overdose may result in an enhanced growth of ears, nose, lips, tongue and cheekbone (gigantism and/ or acromegaly).
Dolgoročno preveliko odmerjanje lahko povzroči močnejšo rast uhljev, nosu, ustnic, jezika in ličnic (gigantizem in/ ali akromegalija).
These signs are consistent with the known effects of excess in human growth hormone.
Ti znaki se skladajo z učinki, znanimi pri presežku človeškega rastnega hormona.
If you forget to take NutropinAq
Če ste pozabili vzeti zdravilo NutropinAq
The prescribed dosage regimen should be continued.
Nadaljevati je treba predpisani režim odmerjanja.
A disruption or early ending of the treatment with somatropin may impair the success of the growth hormone therapy.
Prekinitev ali zgodnje končanje zdravljenja s somatropinom lahko poslabša uspeh zdravljenja z rastnim hormonom.
Please ask the doctor for advice before stopping the treatment.
Preden prekinete zdravljenje, se posvetujte z zdravnikom.
Like all medicines, NutropinAq can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo NutropinAq neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
The common side effects reported were injection site reactions, headache, excessive tension of the muscles (hypertonia), subnormal activity of the thyroid gland (hypothyroidism), impaired glucose tolerance, loss of strength (asthenia) and development of antibodies to the protein somatropin.
Pogosti neželeni učinki so bili reakcije na mestu injiciranja, glavobol, čezmerna napetost mišic (hipertonija), nezadostno delovanje žleze ščitnice (hipotiroidizem), motena toleranca za glukozo, izguba moči (astenija) in pojav protiteles proti beljakovini somatropinu.
An accumulation of fluids in the body with a mild transient swelling of the hands and feet (oedema), muscular pain (myalgia) and arthralgia (neuralgic pain in one or more joints) were seen very commonly in adult patients and commonly in children.
Pri odraslih bolnikih so zelo pogosto, pri otrocih pa pogosto poročali o kopičenju tekočine v telesu z blagim, prehodnim otekanjem rok in stopal (edemi), bolečinah v mišicah (mialgiji) in artralgiji (nevralgični bolečini v enem ali več sklepih).
In patients with Turner syndrome, abnormally heavy bleeding at menstruation was commonly reported.
Pri bolnicah s Turnerjevim sindromom so pogosto poročali o nenormalno močnih menstruacijskih krvavitvah.
In patients with chronic renal insufficiency, renal failure, peritonitis, bone necrosis, increase of creatinine blood levels were commonly reported.
Pri bolnikih s kronično insuficienco ledvic so pogosto poročali o odpovedi ledvic, peritonitisu, nekrozi kosti in zvišanju koncentracije kreatinina v krvi.
Abnormal sensations (paraesthesia) were seen very commonly in adults with growth hormone deficiency.
Pri odraslih s pomanjkanjem rastnega hormona so zelo pogosto zabeležili nenormalne zaznave (parestezije).
These patients also reported the following common side effects: abnormally high levels of blood glucose, an excess of lipids in the blood, sleeplessness, joint disorders, arthrosis, muscular debility, back pain, breast pain and breast enlargement (gynaecomastia).
Ti bolniki so imeli tudi naslednje pogoste neželene učinke: nenormalno visoko koncentracijo glukoze v krvi, preveč lipidov v krvi, nespečnost, sklepne motnje, artrozo, mišično šibkost, bolečine v hrbtu, bolečine v prsih in povečanje prsi (ginekomastijo).
Other less common side effects have been reported:
Drugi manj pogosti neželeni učinki, ki so bili opisani:
Those occurring at the injection site: injection site atrophy, injection site haemorrhage, injection site mass and hypertrophy.
Na mestu injiciranja: atrofija na mestu injiciranja, krvavitev na mestu injiciranja, masa na mestu injiciranja, hipertrofija
Metabolic disorders: decrease in blood glucose, increase in phosphate levels in the blood.
Presnovne motnje: znižanje glukoze v krvi, zvišanje koncentracije fosfata v krvi.
Nervous disorders: somnolence, rapid involuntary movements of the eyes (nystagmus), personality disorder, vertigo.
Bolezni živčevja: somnolenca, hitro nehotno gibanje zrkel (nistagmus), osebnostna motnja, vrtoglavica.
Those related to the heart: abnormally rapid heart rate (tachycardia), high blood pressure.
Povezani s srcem: nenormalno hiter srčni utrip (tahikardija), visok krvni tlak.
Those related to the stomach: vomiting, abdominal pain, flatulence, feeling of sickness, and rarely diarrhoea.
Povezani z želodcem: bruhanje, bolečine v trebuhu, napenjanje, občutek slabosti v želodcu in, redko, driska.
Those affecting the skin: lipodystrophy (disturbed fat metabolism), skin atrophy, exfoliative inflammation of the skin, urticaria (allergic disorder marked by raised oedematous patches of skin or mucus membrane), excessive growth of hair on the face and body (hirsutism), skin hypertrophy.
Na koži: lipodistrofija (motena presnova maščob), atrofija kože, eksfoliativno vnetje kože, koprivnica (alergijska motnja z dvignjenimi, oteklimi lehami na koži ali sluznicah), čezmerna rast dlak na obrazu in telesu (hirzutizem), hipertrofija kože.
Those related to the musculoskeletal system: decrease in muscle size (muscle atrophy), bone pain and carpal tunnel syndrome.
Na mišično- skeletnem sistemu: zmanjšanje velikosti mišic (atrofija mišic), bolečine v kosteh in sindrom zapestnega kanala.
Those affecting the urogenital system: urinary incontinence, discharge of mucus from the vagina (leukorrhoea), excessive secretion of urine, urine frequency, urine abnormality, urine haemorrhage.
Na sečilih in spolovilih: urinska inkontinenca, sluzast izcedek iz nožnice (levkoreja), čezmerno izločanje urina, pogosto uriniranje, nepravilnosti urina, kri v urinu.
Other possible side effects: neoplasm, anaemia, papilloedema, diplopia.
Drugi možni neželeni učinki: neoplazma, anemija, papiledem, diplopija.
Increased growth of birthmarks or moles (pre-existing naevi) may occur.
Pojavi se lahko izrazitejša rast materinih znamenj (že obstoječih nevusov).
The doctor should be consulted as soon as possible if any changed appearance of the skin is noticed.
Če opazite kakršnokoli spremembo videza kože, se morate čim prej posvetovati z zdravnikom.
As with all protein medicines, in a few patients antibodies may develop to the protein somatropin.
27 Kot velja za vsa beljakovinska zdravila, se lahko pri maloštevilnih bolnikih pojavijo protitelesa proti beljakovini somatropinu.
Growth hormone antibodies with very low binding capacity have not been associated with adversely affected growth rate.
Protitelesa proti rastnemu hormonu z zelo majhno vezavno kapaciteto niso povezana z neugodnim vplivom na hitrost rasti.
27 Leukaemia has been reported in a small number of growth hormone deficient patients treated with growth hormone.
Pri majhnem številu bolnikov s pomanjkanjem rastnega hormona, zdravljenih s tem hormonom, je bila opisana levkemija.
Symptoms of benign increased brain pressure (benign intracranial hypertension), which are papilloedema, visual changes, headache, nausea and vomiting, may occur more often in children with chronic renal insufficiency receiving NutropinAq.
Simptomi benignega zvišanja možganskega tlaka (benigne intrakranialne hipertenzije) – papiledem, spremembe vida, glavobol, siljenje na bruhanje in bruhanje – se lahko pogosteje pojavijo pri otrocih s kronično insuficienco ledvic, ki dobivajo NutropinAq.
HOW TO STORE NutropinAq
SHRANJEVANJE ZDRAVILA NutropinAq
After first use, the cartridge may be stored for up to 28 days at 2°C - 8°C.
Po prvi uporabi lahko vložek shranjujete največ 28 dni pri temperaturi med 2 °C in 8 °C.
Do not use NutropinAq after the expiry date which is stated on the label of the cartridge and the carton after EXP.
Zdravila NutropinAq ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na vložku in škatli poleg oznake EXP / Uporabno do.
Do not use NutropinAq if you notice that the solution is cloudy.
NutropinAq ne uporabite, če opazite, da je raztopina motna.
− The active substance of NutropinAq is somatropin*. * human growth hormone produced in Escherichia coli cells by recombinant DNA technology.
* humani rastni hormon, pridobljen iz celic Escherichie coli z genskim inženirstvom.
− The other ingredients are sodium chloride, phenol, polysorbate 20, sodium citrate, citric acid anhydrous and water for injections.
- Pomožne snovi so natrijev klorid, fenol, polisorbat 20, natrijev citrat, brezvodna citronska
NutropinAq is a solution for injection (in a cartridge (10 mg/ 2ml) - pack size of 1, 3 and 6).
NutropinAq je raztopina za injiciranje (v vložku (10 mg/ 2 ml) – pakiranje 1, 3 in 6).
The solution for multidose use is clear, colourless and sterile.
Raztopina za večkratno uporabo je bistra, brezbarvna in sterilna.
28 Marketing Authorisation Holder:
28 Imetnik dovoljenja za promet z zdravilom:
IPSEN Ltd, 190 Bath Road, Slough, Berkshire, SL1 3XE, UK
190 Bath Road, Slough, Berkshire, SL1 3XE, Velika Britanija
IPSEN PHARMA BIOTECH S. A. S., Parc d’ Activités du Plateau de Signes, CD no 402, 83870 Signes, France
IPSEN PHARMA BIOTECH S. A. S., Parc d’ Activités du Plateau de Signes, CD no 402, 83870 Signes, Francija
Č eská republika Beaufour Ipsen Pharma Evropská 136/ 810 CZ-160 00 Praha 6 Č eská republika Tel: + 420 242 481 821
Česká republika Beaufour Ipsen Pharma Evropská 810/ 136 CZ- 160 00 Praha 6 Česká republika Tel: + 420 242 481 821
29 España Ipsen Pharma S. A.
29 România, България España Beaufour Ipsen Pharma Ipsen Pharma S. A.
Slovenija PharmaSwiss d. o. o.
Slovenija France PharmaSwiss, d. o. o.
Dolenjska cesta 242c SI-1000 Ljubljana Tel: + 386 1 236 47 00
Ipsen Pharma Dolenjska cesta 242c 65 quai Georges Gorse SI- 1000 Ljubljana F- 92100 Boulogne- Billancourt Tel: + 386 1 236 47 00 Tél: + 33 - 1 - 44 96 13 13
30 NutropinAq Pen Instructions for use with NutropinAq
30 NutropinAq Pen Navodila za uporabo injekcijskega peresnika NutropinAq
As shown by the illustrations below, NutropinAq pen and cartridges are available in two designs (with or without additional yellow colour). The working of the pen and the content of the cartridges are the same for both designs.
Delovanje injekcijskega peresnika in vložkov je enako pri obeh zunanjih podobah.
Always refer to the LCD (Liquid Crystal Display), not audible clicks, for setting an injection of NutropinAq.
Za nastavitev odmerka NutropinAq se ne smete zanašati na slišne klike, ampak morate vedno uporabiti prikazovalnik LCD (prikazovalnik s tekočimi kristali).
Always store the pen and cartridges in a clean, safe place in the refrigerator at a temperature between 2-8°C and out of children’ s reach and sight.
Injekcijski peresnik in vložke vedno shranjujte na čistem, varnem mestu v hladilniku, pri temperaturi med 2 °C in 8 °C in nedosegljive otrokom.
The NutropinAq is designed to withstand a nominal (one hour maximum) period of time outside of the refrigerator on a daily basis.
NutropinAq je izdelan tako, da lahko prestane vsakodnevno nominalno (največ enourno) obdobje zunaj hladilnika.
• Wash your hands thoroughly with soap and water before using your pen. • Clean the cartridge rubber seal with an alcohol swab or cotton ball saturated with alcohol. • Avoid touching the cartridge rubber seal at all times. • If you accidentally touch the cartridge rubber seal, clean it with an alcohol swab. • Do not use the same needle for more than one person. • Use needles only once.
• Pred uporabo injekcijskega peresnika si dobro umijte roke z milom in vodo. • Očistite gumijasto zaporo vložka s kosmom vate, prepojene z alkoholom, ali z alkoholnim zložencem. • Ne dotikajte se gumijaste zapore vložka. • Če se po nesreči dotaknete gumijaste zapore, jo očistite z alkoholnim zložencem. • Posamezne igle ne uporabljajte za več kot eno osebo. • Iglo uporabite samo enkrat.
31 Shown below are the items necessary for giving an injection.
Spodaj so narisani deli, potrebni za injiciranje.
Your NutropinAq cartridge and Pen will be supplied separately.
31 NutropinAq vložek in Pen boste dobili posebej.
Part I:
I. del:
Preparing and Injecting
Priprava in injiciranje
Occasionally, after refrigeration, you may notice that small colourless particles are present in the NutropinAq solution.
Včasih boste po shranjevanju v hladilniku v raztopini NutropinAq opazili drobne, brezbarvne delce beljakovine.
(See illustration.) Then turn the dose knob clockwise until the first click position is reached (approximately 1/ 4 turn).
Nato črni odmerni gumb zasučite v smeri urnega kazalca, dokler ne doseže položaja prvega klika (približno 1/ 4 obrata).
If this is not done when the dosage knob is first pushed in, NutropinAq will be wasted or the cartridge may crack.
Če tega ne storite, preden odmerni gumb prvič pritisnete, bo šel NutropinAq v nič, vložek pa lahko poči.
Remove the paper seal from a new needle assembly and screw it onto the cartridge holder.
Odstranite papirnato zaščitno nalepko s kompleta z novo iglo in slednjega privijte na držalo vložka.
If medicine doesn’ t appear within a few seconds, you may need to push the reset button again.
Če se zdravilo ne pojavi v nekaj sekundah, boste morali še enkrat pritisniti nastavitveni gumb.
Now turn the black dose knob clockwise (See illustration) by one click (0.1mg).
Zdaj zasučite črni odmerni gumb v smeri urnega kazalca (glejte sliko) za en klik (0, 1 mg).
If you accidentally turn it too far, go back one click (0.1 mg).
Če ga pomotoma preveč zasučete, pojdite en klik (0, 1 mg) nazaj.
While still holding the pen in the upright position, push in the black dose knob again and watch the needle tip for a drop of medicine to appear.
Medtem ko injekcijski peresnik še vedno držite pokonci, znova pritisnite črni odmerni gumb in opazujte, ali se na konici igle pojavi kapljica zdravila.
Prepare the injection site by wiping with an antiseptic impregnated swab.
Pripravite injekcijsko mesto, tako da ga obrišete z zložencem prepojenim z antiseptikom..
Injection sites include the upper arms, abdomen, and upper thighs.
Injekcijska mesta obsegajo nadlakti, trebuh in zgornji del stegen.
Upper Arm
nadlaket
Abdomen
trebuh
Your doctor or nurse will show
Prislonite konico peresa na pripravljeno mesto injiciranja in zabodite iglo v kožo tako, da potisnete injekcijski peresnik navzdol, dokler ni ščitnik pritisnjen do konca.
Now you are ready to administer the dose.
Zdravnik ali medicinska sestra vam bosta pokazala, kako to storiti.
Press down on the black dose knob.
Zdaj ste pripravljeni za injiciranje odmerka.
Attach the pen cap and return it to its case with the black dose knob pressed in.
Namestite pokrovček injekcijskega peresnika in ga, s črnim odmernim gumbom potisnjenim noter, dajte nazaj v škatlico.
For subsequent injections with the NutropinAq Pen, attach a new needle, push the white reset button and dial your dose.
Za nadaljnje injekcije s injekcijskim peresnikom NutropinAq Pen namestite novo iglo, pritisnite beli nastavitveni gumb in nastavite svoj odmerek.
Part II:
II. del:
Storage and Maintenance
Shranjevanje in vzdrževanje